Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

• المؤلفون الرئيسيون: Susanne Klint (مؤلف), Joachim Feldwisch (مؤلف), Lindvi Gudmundsdotter (مؤلف), Karin Dillner Bergstedt (مؤلف), Elin Gunneriusson (مؤلف), Ingmarie Höidén Guthenberg (مؤلف), Anders Wennborg (مؤلف), Andrew C. Nyborg (مؤلف), Amol P. Kamboj (مؤلف), Paul M. Peloso (مؤلف), David Bejker (مؤلف), Fredrik Y. Frejd (مؤلف)
• التنسيق: كتاب
• منشور في: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

ABSTRACTPsoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatm...